Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Cardiopulmonary bypass and arrest of the heart during cardiac surgery are necessary to allow
the surgeon to perform heart operations. However, these processes can cause injury to the
heart which may worsen post-operative outcomes. In fact, the effects of these injuries may
continue after surgery, and lead to a long-term decrease in heart function. Neonates and
young infants are at particular risk for this occurrence.
While much research has been done in adults looking for medicines that might protect the
heart during surgery, few studies have been conducted in neonates and young infants. The
investigators are testing Dexrazoxane, which has proven to be cardio-protective in pediatric
cancer patients, in the hope that it may lessen cardiac injury during and after congenital
heart surgery, and thereby improve outcomes in the neonatal and young infant population.
In order to accomplish this, the investigators must first determine how Dexrazoxane can be
safely administered to young children with congenital heart disease.